New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 23, 2014
04:55 EDTACRX, ACRX, BLRX, BLRX, CRIS, CRIS, NEO, NEO, PRTA, PRTA, PTCT, PTCT, LGND, LGND, GALE, GALE, IPCI, IPCIRoth Capital to hold a conference
ROTH Healthcare Corporate Access Day to be held in London, England on June 23-24.
News For ACRX;BLRX;CRIS;NEO;PRTA;PTCT;LGND;GALE;IPCI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 3, 2015
10:28 EDTPTCTHigh option volume stocks
Subscribe for More Information
09:12 EDTNEONeoGenomics overhang should dissipate, says Roth Capital
Subscribe for More Information
September 2, 2015
10:00 EDTACRXOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: AcelRx (ACRX) initiated with a Buy at H.C. Wainwright... Adobe (ADBE) initiated with a Perform at Oppenheimer... Antero Midstream (AM) initiated with a Buy at Ladenburg... Arbutus Biopharma (ABUS) initiated with an Outperform at JMP Securities... CSI Compressco (CCLP) initiated with a Market Perform at Wells Fargo... Cepheid (CPHD) initiated with an Equal Weight at Barclays... Cincinnati Financial (CINF) initiated with a Buy at MKM Partners... Disney (DIS) initiated with an Outperform at CLSA... Genomic Health (GHDX) initiated with an Underweight at Barclays... Green Brick (GRBK) initiated with a Neutral at Citi... Heron Therapeutics (HRTX) initiated with a Buy at BofA/Merrill... Karyopharm (KPTI) initiated with an Overweight at JPMorgan... PayPal (PYPL) initiated with a Buy at Argus... Quidel (QDEL) initiated with an Overweight at Barclays... Recro Pharma (REPH) initiated with a Buy at H.C. Wainwright.
07:05 EDTACRXAcelRx initiated with a Buy at H.C. Wainwright
Subscribe for More Information
07:02 EDTNEONeoGenomics enters into national agreement with Premier, Inc.
NeoGenomics announced that it has entered into a national group purchasing agreement with Premier, Inc. Premier is a leading healthcare improvement company uniting an alliance of approximately 3,600 U.S. hospitals and 120,000 other providers, and is widely recognized as operating one of the largest healthcare group purchasing organizations in the United States. The three year agreement secures for NeoGenomics the distinction of becoming the first specialized oncology reference laboratory to become a preferred in-network lab option for all Premier member hospitals, cancer centers, pathology groups, and oncology/physician providers nationwide.
September 1, 2015
10:24 EDTPTCTOptions with increasing implied volatility: PTCT ARIA MTG
Subscribe for More Information
August 31, 2015
11:32 EDTPTCTOptions with increasing implied volatility: PTCT ARIA
Subscribe for More Information
10:03 EDTACRXHigh option volume stocks
High option volume stocks: MDCO IR TROV RLGY PAH XRX ACRX
August 28, 2015
11:04 EDTPTCTOptions with increasing implied volatility
Subscribe for More Information
August 27, 2015
10:57 EDTPTCTOptions with increasing implied volatility
Subscribe for More Information
August 26, 2015
10:36 EDTPTCTOptions with increasing implied volatility
Options with increasing implied volatility: UVXY PTCT VIX SVXY SUNE SQQQ SPXS LPI
August 25, 2015
09:59 EDTPTCTOn The Fly: Analyst Initiation Summary
Subscribe for More Information
08:01 EDTPTCTPTC Therapeutics initiated with a Buy at Citi
Subscribe for More Information
August 24, 2015
15:44 EDTPTCTOptions with increasing implied volatility
Subscribe for More Information
13:15 EDTLGNDFDA expands use of Novartis' Promacta to include children ages 1 and older
Ligand Pharmaceuticals (LGND) announced that the FDA has approved an expanded use for Promacta, a Novartis (NVS) product, to include children 1 year of age and older with chronic immune thrombocytopenia who have had an insufficient response to corticosteroids, immunoglobulins or splenectomy. Promacta was acquired by Novartis in March from GlaxoSmithKline (GSK). Promacta was discovered as a result of research collaboration between GSK and Ligand Pharmaceuticals and was developed by GSK. The updated label also includes a new oral suspension formulation of Promacta that is designed for younger children who may not be able to swallow tablets. Promacta was approved by the FDA as a tablet formulation in June 2015 for children 6 years of age and older and in 2008 for use in adult patients with the same condition. The label expansion of Promacta was based on data from two double-blind, placebo-controlled trials, including the largest Phase 3 clinical trial in this patient population. Treatment with Promacta significantly increased and sustained platelet counts among pediatric patients with chronic ITP with an insufficient response to prior chronic ITP therapies, and some patients taking concomitant ITP medications were able to reduce or discontinue their use of these medications, primarily corticosteroids. Promacta should be used only in those whose degree of thrombocytopenia and clinical condition increase the risk for bleeding.
10:12 EDTPTCTOptions with increasing implied volatility
Subscribe for More Information
07:07 EDTGALEIDMC recommends reduction of cardiac toxicity monitoring in Galena NeuVax trial
Galena Biopharma announced that the Independent Data Monitoring Committee, or IDMC, has recommended to the company that it can reduce the cardiac toxicity monitoring for patients in its NeuVax Phase 3 Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer with Low to Intermediate HER2 Expression with NeuVax Treatment, or PRESENT, clinical trial. The trial is being run under a Special Protocol Assessment, or SPA, approved by the FDA. Following its most recent IDMC meeting in June, the IDMC recommended routine cardiac monitoring could be reduced in the PRESENT trial and that such a reduction is justified and consistent with the pre-specified Cardiac Toxicity Monitoring Stopping Rules defined in the study protocol. The IDMC concluded that cardiac toxicity monitoring by echocardiogram, or ECHO, or multiple-gated acquisition, or MUGA, scans could be reduced. The IDMC had no other suggestions and recommended the trial continue as planned.
August 21, 2015
10:36 EDTPTCTOptions with increasing implied volatility
Options with increasing implied volatility: PTCT UVXY VIX VXX SVXXY SRPT TZA UPRO VNR SPXU

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use